Figure 4: Distribution (%) of selected drugs approved and priced in 2024 by indication
Oncology
47%
Neurology
20%
Blood disorders
13%
Unclassified orphan drugs/Other
10%
Respiratory disorders
7%
Cardiovascular diseases
7%